Literatur
- 1
Weitz J I.
Low-molecular-weight heparins.
NEJM.
1997;
337
688-698
- 2
Hirsh J, Anand S S, Halperin J L, Fuster V.
Guide
to anticoagulant therapy: Heparin.
Circulation.
2001;
103
2994-3018
- 3
De Swart C A, Nijmeyer B, Roelofs J M, Sixma J J.
Kinetics of
intravenously administered heparin in normal humans.
Blood.
1982;
60
1251-1258
- 4
Glimelius B, Busch C, Hook M.
Binding
of heparin on the surface of cultured human endothelial cells.
Thromb
Res.
1978;
12
773-782
- 5
Mahadoo J, Heibert L, Jaques L B.
Vascular
sequestration of heparin in man.
Thromb Res.
1978;
12
79-90
- 6
Frydman A M, Bara L, Le Roux Y, Woler M, Chauliac F, Samana M M.
The antithrombotic
activity and pharmocokinetics of enoxaparine, a low molecular weight
heparin, in humans given single subcutaneous doses of 20 up to 80 mg.
J Clin
Pharmacol.
1988;
28
609-618
- 7
Bradbrook I D, Magnani H N, Moelker H C. et al .
ORG 10 172: a low
molecular weight heparinoid anticoagulant with a long half-life
in man.
Br J Clin Pharmacol.
1987;
23
667-675
- 8
Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G.
Low-molecular-weight
heparin (enoxaparin) as prophylaxis against venous thromboembolism
after total hip replacement.
NEJM.
1996;
335
696-700
- 9
Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C,
Damiani M, Andrioli G C, Pugliese R, Iorio A, Brambilla G.
Enoxaparin plus compression
stockings compared with compression stockings alone in the prevention
of venous thromboembolism after elective neurosurgery.
NEJM.
1998;
339
80-85
- 10
Geerts W H, Jay R M, Code K I, Chen E, Szalai J P, Saibil E A, Hamilton P A.
A comparison of low-dose heparin
with low-molecular-weight heparin as prophylaxis against venous
thromboembolism after major trauma.
NEJM.
1996;
335
701-707
- 11
Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie A G,
Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P,
Brien W, Haley S, Willan A.
A
comparison of low-molecular-weight heparin administered primarily
at home with unfractionated heparin administered in the hospital
for proximal deep-vein thrombosis.
NEJM.
1996;
334
677-681
- 12
Koopman M MW, Prandoni P, Piovella F, Ockelford P A, Brandjes D PM, van der Meer J,
Gallus A S, Simonneau G, Chesterman C H, Prins M H, Bossuyt P MM, De
Haes H, van den Belt A GM, Sagnard L, D’Azemar P, Büller H R.
Treatment
of venous thrombosis with intravenous unfractionated heparin administered
in the hospital as compared with subcutaneous low-molecular-weight
heparin administered at home.
NEJM.
1996;
334
682-687
- 13
Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V.
Effects of
a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism
in patients with deep-vein thrombosis.
NEJM.
2001;
344
626-631
- 14
Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J -P, Azarian R, Laurent M, Hirsch J -L,
Ferrari E, Bosson J -L, Mottier D, Beau B.
A comparison of low-molecular-weight
heparin with unfractionated heparin for acute pulmonary embolism.
NEJM.
1997;
337
663-669
- 15
Wallentin L, Ohlsson J, Swahn E.
Low-molecular-weight
heparin during instability in coronary artery disease.
Lancet.
1996;
347
561-568
- 16
Klein W, Buchwald A, Hillis S E, Monrad S, Sanz G, Turpie A GG, van der Meer J, Olaisson E,
Undeland S, Ludwig K.
Comparison of low-molecular-weight
heparin with unfractionated heparin acutely and with placebo for
6 weeks in the management of unstable coronary artery disease.
Circulation.
1997;
96
61-68
- 17
Cohen M, Demers C, Gurfinkel E P, Turpie A GG, Fromell G J, Goodman S, Langer A, Califf R M,
Fox K AA, Premmereur J, Bigonzi F.
A comparison of low-molecular
weight heparin with unfractionated heparin for unstable coronary
artery disease.
NEJM.
1997;
337
447-452
- 18
Antmann E M, McCabe C H, Gurfinkel E P, Turpie A GG, Bernink P JLM, Salein D, de
Luna A B, Fox K, Lablanche J -M, Radley D, Premmereur J, Braunwald E.
Enoxaparin
prevents death and cardiac ischemic events in unstable angina/non-Q-wave
myocardial infarction. Results of the thrombolysis in myocardial
infarction (TIMI) 11B trial.
Circulation.
1999;
100
1593-1601
- 19
Yusuf S. for the Direct Thrombin Inhibitor Trialists’ Collaborative
Group .
Direct thrombin inhibitors in acute coronary
syndromes: principal results of a meta-analysis based on individual patients’ data.
Lancet.
2002;
359
294-302
- 20
Montalescot G, Polle V, Collet J P, Leprince P, Bellanger A, Gandjbakhch I, Thomas D.
Low
molecular weight heparin after mechanical heart valve replacement.
Circulation.
2000;
101
1083-1086
- 21
Kay R, Wong K S, Vu Y L, Chan Y W, Tsoi T H, Ahuja A T, Chan F L, Fong K Y, Law C B,
Wong A, Woo J.
Low-molecular-weight heparin
for the treatment of acute ischemic stroke.
NEJM.
1995;
333
1588-1593
- 22
Brott T, Bogousslavsky J.
Treatment of acute
ischemic stroke.
NEJM.
2000;
343
710-722
- 23
Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S.
Absence of transplacental
passage of the low molecular weight heparin enoxaparin.
Haemostasis.
2000;
30
243-248
- 24
Sanson B J, Lensing A W, Prins M H, Ginsberg J S, Barkagan Z S, Lavenne-Pardonge E,
Brenner B, Dulitzky M, Nielsen J D, Boda Z, Turi S, Mac-Gillavry M R, Hamulyak K,
Theunissen I M, Hunt B J, Buller H R.
Safety of low-molecular-weight
heparin in pregnancy: a systematic review.
hromb Haemost.
1999;
81
668-672
- 25
Malsch R, Harenberg J, Guerrini M, Torri G, Casu B, Heene D L.
Semisynthesis and
analysis of lipophilically modified unfractionated and low molecular
mass heparins.
Semin Thromb Hemost.
1994;
20
182-192
- 26
Warkentin T E, Levine M N, Hirsh J, Horsewood P, Roberts R S, Gent M, Kelton J G.
Heparin-induced thrombocytopenia
in patients treated with low-molecular-weight heparin or unfractionated
heparin.
N Engl J Med.
1995;
332
1330-1335
- 27
Muir J M, Hirsh J, Weitz J I, Andrew M, Young E, Shaughnessy S G.
A histomorphometric
comparison of the effects of heparin and low-molecular-weight heparin
on cancellous bone in rats.
Blood.
1997;
89
3236-3242
- 28
Bhandari M, Hirsh J, Weitz J I, Young E, Venner T J, Shaughnessy S G.
The effects
of standard and low molecular weight heparin on bone nodule formation
in vitro.
Thromb Haemost.
1998;
80
413-417
- 29
Smith B S, Gandhi P J.
Pharmacokinetics
and phamacodynamics of low-molecular-weight heparins and glycoprotein
IIb/IIIa receptor antagonists in renal failure.
J
Thrombosis Thrombolysis.
2001;
11
39-48
- 30
Turpie A GG, Gallus A S, Hoek J A.
A synthetic pentasaccharide for the prevention
of deep-vein thrombosis after total hip replacement.
NEJM.
2001;
344
619-625
- 31
Eriksson B I, Bauer K A, Lassen M R, Turpie A GG.
Fondaparinux
compared with enoxaparin for the prevention of venous thromboembolism
after hip-fracture surgery.
NEJM.
2001;
345
1298-1304
- 32
Bauer K A, Eriksson B I, Lassen M R, Turpie A GG.
Fondaparinux
compared with enoxaparin for the prevention of venous thromboembolism
after elective major knee surgery.
NEJM.
2001;
345
1305-1310
Autoren
Dr. F. Schröder,
Dr. T. Weiss
Abteilung
für Kardiologie und Angiologie, Medizinischen Hochschule
Hannover
Carl-Neuberg-Straße 1
30625 Hannover
